Developing future food and health leaders

Developing future food and health leaders

UC Davis’ Innovation Institute for Food and Health, UC Investments and Denmark’s Novo Nordisk Foundation today announced a unique collaboration to develop international leaders in food and planetary health. The first-of-its-kind program will give biotechnology-focused Ph.D. and postdoctoral students in Denmark and the United States the training and experience needed to effectively apply their university research into companies that accelerate po…

The company's letter and THEMA's response

Novo Nordisk will spend no less than $2 billion to strengthen its position in the obesity market. The pharmaceutical company has developed a series of new-generation drugs, including the "triple G" from United Laboratories International 3933.HK.

Novo adds to obesity drug pipeline via $200M deal with China-based biotech

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.

Novo Nordisk Bets $200M on Triple-Targeting Drug for Obesity and Other Metabolic Diseases – RamaOnHealthcare

Novo Nordisk is licensing rights to a United Biotechnology drug that sparks metabolic effects by binding to and activating receptors for GLP-1, GIP, and

Novo Nordisk Bets $200M on Triple-Targeting Drug for Obesity and Other Metabolic Diseases

Novo Nordisk is licensing rights to a United Biotechnology drug that sparks metabolic effects by binding to and activating receptors for GLP-1, GIP, and glucagon. Separately, the pharma giant said its recently announced discounted price for obesity medication Wegovy is now expanding to traditional pharmacies. The post Novo Nordisk Bets $200M on Triple-Targeting Drug for Obesity and Other Metabolic Diseases appeared first on MedCity News.